Prostate Cancer Foundation Scientific Retreat VL

PROPHECY Trial: Circulating Tumor Cell as a Biomarker in mCRPC - Andrew Armstrong

Details
(Length of Discussion: 12 min) Charles Ryan and Andrew Armstrong discuss the PROPHECY study, a PCF challenge award, co-funded by Movember. Seeing the future with predictive biomarkers was the foundational vision for this study. For men with castration-resistant prostate cancer undergoing a range of therapies, two AR-V7 tests were prospectively compared to see how well they predicted both progressi...

STAMPEDE Trial Updates in Prostate Cancer - Silke Gillessen

Details
(Length of Discussion: 12 min) Silke Gillessen and Alicia Morgans discuss recent data from the STAMPEDE trial that was released at ESMO 2018. Local radiotherapy improving survival in metastatic prostate cancer with low disease burden and the subanalysis looking at effects of abiraterone acetate plus prednisone in both high and low metastatic hormone sensitive prostate cancer. Silke articulates the...

Diagnostic Imaging and Therapeutic Aspect of PSMA in Prostate Cancer by Michael Hofman

Details
(Length of Discussion: 13 min) Michael Hofman discusses with Alicia Morgans both the diagnostic and therapeutic aspect of prostate specific membrane antigen (PSMA) in prostate cancer. The sensitivity and specificity of the PSMA PET may offer relevant clinical advantages in the diagnosis of prostate cancer while the physical properties of Lutetium 177 may provide advantages therapeutically. Biograp...

Results from TRITON2: Treatment of mCRPC with Rucaparib - Alan Bryce

Details
(Length of Discussion: 8 min) Charles Ryan and Alan Bryce discuss TRITON2 results that provide a compelling rationale for evaluating rucaparib, a potent PARP1, PARP2 and PARP3 inhibitor, in patients with mCRPC associated with homologous recombination deficiency. Alan presents the molecular selection criteria, the design of the trial and the initial look at the first 85 patients in this study of he...

A Review on Practice Informing Prostate Cancer Study Results - Christopher Sweeney

Details
(Length of Conversation: 18 min) Christopher Sweeney and Alicia Morgans review practice informing data released at the ESMO 2018 meeting from the GETUG 12, ERA 223, and STAMPEDE studies. Biographies: Christopher Sweeney, MBBS, Professor of Medicine, Harvard Medical School, Medical Oncologist, Dana-Farber Cancer Institute Alicia Morgans, MD, MPH Related Content: 12-Year Follow-Up of GETUG-12, A Pha...

The Prostate Cancer Foundation: a Discussion with Andrea Miyahira

Details
(Length of Discussion: 7 min) Andrea Miyahira and Alicia Morgans discuss the Prostate Cancer Foundation, the largest non-profit organization in the world, focused solely on funding for prostate cancer research and committed to advancing treatments for very late stage patients. Biographies: Andrea K. Miyahira, Ph.D., Dr. Andrea Miyahira has a Ph.D. in cancer immunology and is Director of Research a...

The Process of Metastasis in Prostate Cancer - Kenneth Pienta

Details
(Length of Discussion: 16 min) Charles Ryan and Ken Pienta discuss the process of metastasis in prostate cancer, referring to the seed and soil hypothesis and the influence of the tumor microenvironment and immune system. Biography: Kenneth J. Pienta, MD, The Donald S. Coffey Professor of Urology, Professor of Oncology, Professor of Pharmacology and Molecular Sciences, The Johns Hopkins Hospital R...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe